$TOVX
Theriva Biologics, Inc.

2022 Q1 Form 10-Q Financial Statement

#000141057822001679 Filed on May 16, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.455M $1.419M
YoY Change 2.54% 1.87%
% of Gross Profit
Research & Development $2.597M $1.118M
YoY Change 132.29% -31.62%
% of Gross Profit
Depreciation & Amortization $18.00K $33.00K
YoY Change -45.45% -43.1%
% of Gross Profit
Operating Expenses $4.252M $2.537M
YoY Change 67.6% -16.22%
Operating Profit -$4.252M -$2.537M
YoY Change 67.6%
Interest Expense -$21.00K $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net -$21.00K $0.00
YoY Change
Pretax Income -$4.273M -$2.537M
YoY Change 68.43% -15.15%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$4.273M -$2.536M
YoY Change 68.49% -14.44%
Net Earnings / Revenue
Basic Earnings Per Share -$0.03 -$0.13
Diluted Earnings Per Share -$0.03 -$0.13
COMMON SHARES
Basic Shares Outstanding 138.2M 90.81M
Diluted Shares Outstanding 138.2M 90.81M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $56.69M $76.89M
YoY Change -26.27% 662.39%
Cash & Equivalents $56.69M $76.89M
Short-Term Investments
Other Short-Term Assets $1.142M $1.749M
YoY Change -34.71% 61.35%
Inventory
Prepaid Expenses
Receivables
Other Receivables $127.0K
Total Short-Term Assets $59.56M $78.64M
YoY Change -24.26% 604.06%
LONG-TERM ASSETS
Property, Plant & Equipment $302.0K $395.0K
YoY Change -23.54% -43.17%
Goodwill $5.809M
YoY Change
Intangibles $21.87M
YoY Change
Long-Term Investments
YoY Change
Other Assets $126.0K $23.00K
YoY Change 447.83% 0.0%
Total Long-Term Assets $29.44M $418.0K
YoY Change 6944.02% -41.78%
TOTAL ASSETS
Total Short-Term Assets $59.56M $78.64M
Total Long-Term Assets $29.44M $418.0K
Total Assets $89.00M $79.05M
YoY Change 12.58% 565.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.354M $621.0K
YoY Change 118.04% -50.2%
Accrued Expenses $1.535M $1.501M
YoY Change 2.27% -7.86%
Deferred Revenue
YoY Change
Short-Term Debt $68.00K $0.00
YoY Change
Long-Term Debt Due $68.00K
YoY Change
Total Short-Term Liabilities $10.98M $2.122M
YoY Change 417.25% -26.22%
LONG-TERM LIABILITIES
Long-Term Debt $229.0K $0.00
YoY Change
Other Long-Term Liabilities $6.039M $108.0K
YoY Change 5491.67% -73.33%
Total Long-Term Liabilities $6.268M $108.0K
YoY Change 5703.7% -73.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.98M $2.122M
Total Long-Term Liabilities $6.268M $108.0K
Total Liabilities $20.97M -$544.0K
YoY Change -3955.15% -234.99%
SHAREHOLDERS EQUITY
Retained Earnings -$275.6M
YoY Change
Common Stock $343.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $68.03M $79.60M
YoY Change
Total Liabilities & Shareholders Equity $89.00M $79.05M
YoY Change 12.58% 565.05%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$4.273M -$2.536M
YoY Change 68.49% -14.44%
Depreciation, Depletion And Amortization $18.00K $33.00K
YoY Change -45.45% -43.1%
Cash From Operating Activities -$4.902M -$3.328M
YoY Change 47.3% -32.9%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $14.00K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$4.280M
YoY Change
Cash From Investing Activities -$4.280M -$14.00K
YoY Change 30471.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $66.00M
YoY Change -100.0%
Debt Paid & Issued, Net $1.376M
YoY Change
Cash From Financing Activities -1.376M 74.00M
YoY Change -101.86%
NET CHANGE
Cash From Operating Activities -4.902M -3.328M
Cash From Investing Activities -4.280M -14.00K
Cash From Financing Activities -1.376M 74.00M
Net Change In Cash -10.53M 70.66M
YoY Change -114.9% -1524.6%
FREE CASH FLOW
Cash From Operating Activities -$4.902M -$3.328M
Capital Expenditures $0.00 $14.00K
Free Cash Flow -$4.902M -$3.342M
YoY Change 46.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
138201442
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
90807693
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000894158
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-12584
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
SYNTHETIC BIOLOGICS, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-3808303
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
9605 Medical Center Drive, Suite 270
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Rockville
CY2022Q1 dei Entity Address Country
EntityAddressCountry
MD
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20850
CY2022Q1 dei City Area Code
CityAreaCode
301
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
417-4364
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2022Q1 dei Trading Symbol
TradingSymbol
SYN
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
158437840
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56692000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
67325000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2863000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1533000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
59555000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
68858000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
302000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
101000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
103000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1338000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1383000
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
21869000
CY2022Q1 us-gaap Goodwill
Goodwill
5809000
CY2022Q1 syn Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
23000
CY2021Q4 syn Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
23000
CY2022Q1 us-gaap Assets
Assets
88999000
CY2021Q4 us-gaap Assets
Assets
70365000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1354000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
524000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1535000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1928000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
423000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
978000
CY2022Q1 syn Contingent Consideration Current Portion
ContingentConsiderationCurrentPortion
7470000
CY2022Q1 us-gaap Loans Payable Current
LoansPayableCurrent
68000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
126000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
124000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
10976000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3554000
CY2022Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
4688000
CY2022Q1 us-gaap Long Term Loans Payable
LongTermLoansPayable
229000
CY2022Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
3728000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1351000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1403000
CY2022Q1 us-gaap Liabilities
Liabilities
20972000
CY2021Q4 us-gaap Liabilities
Liabilities
4957000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
158440168
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
158437840
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
132044866
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
132042538
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
158000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
132000
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
343245000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
336560000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
181000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-275557000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-271284000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
68027000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
65408000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
88999000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
70365000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1655000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1419000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2597000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1118000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
4252000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
2537000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4252000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2537000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-23000
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
0
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-21000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
0
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-4273000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-2537000
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
CY2021Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4273000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2536000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4273000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11459000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
138201442
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
90807693
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-4273000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-2537000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-181000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-4454000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-2537000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
0
CY2021Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
1000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4454000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2536000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
65408000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
112000
CY2022Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
6599000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
181000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4273000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
68027000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-7540000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
101000
CY2021Q1 syn Stock Issued During Period At Market Offering Value
StockIssuedDuringPeriodAtMarketOfferingValue
65960000
CY2021Q1 syn Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
8042000
CY2021Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
24000
CY2021Q1 syn Adjustments To Effect Of Preferred Stock Price
AdjustmentsToEffectOfPreferredStockPrice
0
CY2021Q1 syn Conversionofseriesbpreferredstocktocommonstock
Conversionofseriesbpreferredstocktocommonstock
12822000
CY2021Q1 syn Conversion Of Series B Preferred Stock To Common Stock
ConversionOfSeriesBPreferredStockToCommonStock
0
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2536000
CY2021Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1000
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
76824000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-4273000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-2537000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
112000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
101000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
18000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
33000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-390000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
42000
CY2022Q1 syn Increase Decrease Right Of Use Assets
IncreaseDecreaseRightOfUseAssets
45000
CY2021Q1 syn Increase Decrease Right Of Use Assets
IncreaseDecreaseRightOfUseAssets
39000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
13000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-265000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-513000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-71000
CY2022Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-645000
CY2021Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-518000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-49000
CY2021Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-68000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4902000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3328000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14000
CY2022Q1 us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
3863000
CY2021Q1 us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
0
CY2022Q1 syn Repayment Of Long Term Loans From Vendors
RepaymentOfLongTermLoansFromVendors
417000
CY2021Q1 syn Repayment Of Long Term Loans From Vendors
RepaymentOfLongTermLoansFromVendors
0
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4280000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14000
CY2022Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1376000
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
65960000
CY2022Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
8042000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1376000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
74002000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28000
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10530000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
70660000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
67325000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6227000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56795000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76887000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56692000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
76887000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
103000
CY2021Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
0
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56795000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76887000
CY2022Q1 syn Fair Value Of Contingent Consideration In Business Combination
FairValueOfContingentConsiderationInBusinessCombination
12158000
CY2021Q1 syn Fair Value Of Contingent Consideration In Business Combination
FairValueOfContingentConsiderationInBusinessCombination
0
CY2022Q1 syn Fair Value Of Equity Issued As Consideration In Business Combination
FairValueOfEquityIssuedAsConsiderationInBusinessCombination
6599000
CY2021Q1 syn Fair Value Of Equity Issued As Consideration In Business Combination
FairValueOfEquityIssuedAsConsiderationInBusinessCombination
0
CY2022Q1 syn Adjustment Of Pre Close Vcn Financing
AdjustmentOfPreCloseVcnFinancing
417000
CY2021Q1 syn Adjustment Of Pre Close Vcn Financing
AdjustmentOfPreCloseVcnFinancing
0
CY2022Q1 syn Preferred Stock Price Adjustment
PreferredStockPriceAdjustment
0
CY2021Q1 syn Preferred Stock Price Adjustment
PreferredStockPriceAdjustment
7402000
CY2022Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0
CY2021Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
2477000
CY2022Q1 syn Deemed Dividends With Beneficial Conversion Feature
DeemedDividendsWithBeneficialConversionFeature
0
CY2021Q1 syn Deemed Dividends With Beneficial Conversion Feature
DeemedDividendsWithBeneficialConversionFeature
1497000
CY2022Q1 us-gaap Dividends Preferred Stock Paidinkind
DividendsPreferredStockPaidinkind
0
CY2021Q1 us-gaap Dividends Preferred Stock Paidinkind
DividendsPreferredStockPaidinkind
23000
CY2021Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022Q1 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
4700000
CY2022Q1 syn Business Combination Acquired Receivable Fair Value Effectively Settled
BusinessCombinationAcquiredReceivableFairValueEffectivelySettled
417000
CY2022Q1 us-gaap Business Combination Consideration Transferred Equity Interests Issued And Issuable
BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
6599000
CY2022Q1 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
12159000
CY2022Q1 us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
23874000
CY2022Q1 us-gaap Goodwill
Goodwill
5800000
CY2022Q1 us-gaap Income Loss From Subsidiaries Net Of Tax
IncomeLossFromSubsidiariesNetOfTax
197000
CY2022Q1 us-gaap Goodwill
Goodwill
5800000
CY2022Q1 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Indefinite Lived Intangible Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
21700000
CY2022Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022Q1 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
5765000
CY2022Q1 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-44000
CY2022Q1 us-gaap Goodwill
Goodwill
5809000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
101000
CY2022Q1 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
12200000
CY2022Q1 syn Amount Receivable From Prior Owner
AmountReceivableFromPriorOwner
1594000
CY2021Q4 syn Amount Receivable From Prior Owner
AmountReceivableFromPriorOwner
0
CY2022Q1 us-gaap Prepaid Insurance
PrepaidInsurance
557000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
803000
CY2022Q1 syn Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
266000
CY2021Q4 syn Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
458000
CY2022Q1 syn Prepaid Consulting Subscriptions And Other Expenses
PrepaidConsultingSubscriptionsAndOtherExpenses
217000
CY2021Q4 syn Prepaid Consulting Subscriptions And Other Expenses
PrepaidConsultingSubscriptionsAndOtherExpenses
272000
CY2022Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
127000
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
0
CY2022Q1 syn Prepaid Manufacturing Expense
PrepaidManufacturingExpense
102000
CY2021Q4 syn Prepaid Manufacturing Expense
PrepaidManufacturingExpense
0
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2863000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1533000
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1456000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
932000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1154000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
831000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
302000
CY2022Q1 syn Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
1008000
CY2021Q4 syn Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
696000
CY2022Q1 syn Accrued Vendor Payments
AccruedVendorPayments
305000
CY2021Q4 syn Accrued Vendor Payments
AccruedVendorPayments
1028000
CY2022Q1 syn Accrued Manufacturing Costs
AccruedManufacturingCosts
126000
CY2021Q4 syn Accrued Manufacturing Costs
AccruedManufacturingCosts
204000
CY2022Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
91000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5000
CY2022Q1 syn Accrued Liabilities Current.
AccruedLiabilitiesCurrent.
1535000
CY2021Q4 syn Accrued Liabilities Current.
AccruedLiabilitiesCurrent.
1928000
CY2022Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
225000
CY2021Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
886000
CY2022Q1 us-gaap Accrued Vacation Current
AccruedVacationCurrent
115000
CY2021Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
92000
CY2022Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
83000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
423000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
978000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6255275
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.61
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
2413
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
75.60
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
145417
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0.36
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
624000
CY2018Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
18600000
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.69
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.38
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.69
CY2021 syn Warrant Exercise Price Adjustment
WarrantExercisePriceAdjustment
900000
CY2020Q4 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
8000000.0
CY2022Q1 syn Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
18000713
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.69
CY2021 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod
11655747
CY2021 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
0.69
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
6344966
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.69
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
6344966
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.69
CY2017Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
9000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4300000
CY2018Q3 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
328000
CY2018Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
18600000
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.38
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.69
CY2021 syn Warrant Exercise Price Adjustment
WarrantExercisePriceAdjustment
880000
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.69
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.69
CY2018Q4 syn Percentage Of Issue Of The Public Offering
PercentageOfIssueOfThePublicOffering
1.20
CY2021Q1 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
8996768
CY2021Q1 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
8996768
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
78700000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
66000000.0
CY2022Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
0
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
103000
CY2022Q1 us-gaap Short Term Borrowings
ShortTermBorrowings
68000
CY2022Q1 us-gaap Long Term Debt
LongTermDebt
229000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
68000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
65000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
63000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
52000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
32000
CY2022Q1 syn Long Term Debt Maturity Year Six
LongTermDebtMaturityYearSix
17000
CY2022Q1 syn Long Term Debt.
LongTermDebt.
297000
CY2022Q1 syn Number Of Operating Lease For Facilities
NumberOfOperatingLeaseForFacilities
2
CY2022Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P63M
CY2022Q1 syn Lease Rent Abatement Period1
LeaseRentAbatementPeriod1
P3M
CY2022Q1 syn Percentage Of Funds To Be Borrowed By Company
PercentageOfFundsToBeBorrowedByCompany
8.5
CY2022Q1 syn Lessee Operating Lease Short Term Agreement Term
LesseeOperatingLeaseShortTermAgreementTerm
P90D
CY2022Q1 syn Lessee Operating Lease Additional Renewal Term
LesseeOperatingLeaseAdditionalRenewalTerm
P5Y
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
107000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
51000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
112000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
79000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1300000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
165000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
327000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
337000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
347000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
357000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
368000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1901000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
424000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1477000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
126000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1351000

Files In Submission

Name View Source Status
0001410578-22-001679-index-headers.html Edgar Link pending
0001410578-22-001679-index.html Edgar Link pending
0001410578-22-001679.txt Edgar Link pending
0001410578-22-001679-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
syn-20220331.xsd Edgar Link pending
syn-20220331x10q.htm Edgar Link pending
syn-20220331x10q001.jpg Edgar Link pending
syn-20220331x10q_htm.xml Edgar Link completed
syn-20220331xex31d1.htm Edgar Link pending
syn-20220331xex32d1.htm Edgar Link pending
syn-20220331_cal.xml Edgar Link unprocessable
syn-20220331_def.xml Edgar Link unprocessable
syn-20220331_lab.xml Edgar Link unprocessable
syn-20220331_pre.xml Edgar Link unprocessable